Billerica, MA, May 24, 2022 – Entegris, Inc. (NASDAQ: ENTG), a world-class supplier of advanced materials and process solutions for high-technology industries, today announced at INTERPHEX 2022 the opening of its new Life Sciences Technology Center. Conference attendees can learn about mission-critical solutions for the manufacturing ecosystem being developed at the new Technology Center at booth #3321. The event takes place at the Javits Center in New York City from May 24 – 26, 2022. Ross Acucena, applications director for Life Sciences at Entegris, will also deliver a keynote focused on fresh challenges emanating from emerging therapies on May 25, at 10:15 AM at the Innovation Stage, booth 1281.
Entegris’ new Life Sciences Technology Center, located in Billerica, MA, offers life sciences customers the opportunity to leverage Entegris’ expertise on cold-chain supply challenges to optimize processes, reduce costs and increase speed-to-market. The world-class laboratory brings Entegris’ tools and technologies together in one place, where customers can test equipment for freeze and thaw processes to determine which products best fit their needs.
“Maintaining product quality, process robustness, reliability and safety is critical for any pharmaceutical product, but novel treatments such as mRNA, gene and cell therapies often require a more intensive approach to their preparation, storage and shipping,” said John Lynch, vice president of Life Sciences at Entegris. “Building on the success of our Aramus™ bag assembles and support in COVID-19 vaccine delivery, we have opened the Entegris Life Sciences Technology Center as part of our commitment to enable biopharmaceutical companies to have the technologies and processes in place to provide life-sustaining and life-improving innovations for people around the world, now and in the future."
As part of its solutions for manufacturing challenges, Entegris’ is now offering Aramus Shaped 2D single-use bags with custom shapes, sizes and assembly configuations for customers’ space and function requirements. They are designed to be resistant to extreme cold temperatures and to withstand gamma sterilization, which makes them a preferred solution for freezing, transporting, storing, and thawing drug substances, like COVID-19 vaccines, cell therapies and gene therapies.
Entegris’ Life Sciences team has developed a broad component ecosystem that can be configured to manage the most demanding process needs, and which may deliver significant benefits, including:
- reduction in total cost of ownership
- reduction in risk of product loss
- ease and speed of implementation
- solution freeze/thaw control and consistency
- increase in security of supply
- improvement in product security
- improvement in purity with low particulate contamination
- access to the latest technology
To learn about how Entegris is supporting the life sciences sector, visit www.entegris.com/life-sciences.
Entegris is a world-class supplier of advanced materials and process solutions for the semiconductor and other high-tech industries. Entegris has approximately 6,850 employees throughout its global operations and is ISO 9001 certified. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, France, Germany, Israel, Japan, Malaysia, Singapore, South Korea and Taiwan. Additional information can be found at www.entegris.com.
For 43 years, INTERPHEX has been, and continues to be, the premier pharmaceutical, biotechnology, and device development and manufacturing event where you can “Experience Science through Commercialization.” Sponsored by the Parenteral Drug Association (PDA), the event is based in New York and brings over 10,000 global industry professionals and 625+ industry leading suppliers. INTERPHEX offers annual domestic and international industry events and educational opportunities around the world. INTERPHEX and INNOPHEX together, offer the very latest intelligence, cutting-edge technologies and state-of-the-art innovation throughout the product development life cycle.
Forward Looking Statements
This news release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “should,” “may,” “will,” “would” or the negative thereof and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements related to Entegris’ presentation at the INTERPHEX 2022 conference; applications for, and benefits of using, Entegris’ products and technologies; and other matters. These statements involve risks and uncertainties, and actual results may differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to, those risk factors and additional information described in Entegris’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Item 1A of Entegris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on February 4, 2022, and in Entegris’ other periodic filings.
Director of Corporate Communications
T +1 978-436-6546
VP of Investor Relations and Treasury
T +1 952-556-1844